Financial reports
10-K
2023 FY
Annual report
13 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
6 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
29 Mar 22
Current reports
8-K
Other Events
26 Mar 24
8-K
Departure of Directors or Certain Officers
14 Mar 24
8-K
Results of Operations and Financial Condition
13 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
8-K
Entry into a Material Definitive Agreement
28 Feb 24
8-K
Proceeds to fully fund first Phase 3 study of cadisegliatin, expected to initiate in mid-2024
28 Feb 24
8-K
Termination of a Material Definitive Agreement
22 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Dec 23
8-K
Other Events
12 Dec 23
8-K
Other Events
20 Nov 23
Registration and prospectus
S-3
Shelf registration
10 Apr 24
D
$50.96 mm in equity / options, sold $50.96 mm, 4 investors
7 Mar 24
424B5
Prospectus supplement for primary offering
28 Feb 24
424B5
Prospectus supplement for primary offering
25 Jun 21
424B3
Prospectus supplement
15 Jun 21
S-3
Shelf registration
3 Jun 21
424B5
Prospectus supplement for primary offering
21 Apr 21
S-3/A
Shelf registration (amended)
9 Apr 21
S-3
Shelf registration
18 Mar 21
424B5
Prospectus supplement for primary offering
14 Jan 21
Proxies
DEF 14A
Definitive proxy
25 Apr 24
DEF 14C
Information statement
25 Sep 23
PRE 14C
Preliminary information
15 Sep 23
DEF 14A
Definitive proxy
26 Apr 23
DEF 14A
Definitive proxy
2 May 22
DEFA14A
Additional proxy soliciting materials
18 Mar 21
DEF 14A
Definitive proxy
18 Mar 21
PRE 14A
Preliminary proxy
8 Mar 21
DEFA14A
Additional proxy soliciting materials
22 May 20
DEFA14A
Additional proxy soliciting materials
30 Apr 20
Other
CT ORDER
Confidential treatment order
22 Jul 21
EFFECT
Notice of effectiveness
14 Jun 21
CORRESP
Correspondence with SEC
9 Jun 21
UPLOAD
Letter from SEC
8 Jun 21
EFFECT
Notice of effectiveness
21 Apr 21
CORRESP
Correspondence with SEC
16 Apr 21
UPLOAD
Letter from SEC
25 Mar 21
CT ORDER
Confidential treatment order
18 Feb 21
EFFECT
Notice of effectiveness
9 Dec 20
CORRESP
Correspondence with SEC
4 Dec 20
Ownership
SC 13D/A
MacAndrews & Forbes Inc.
22 Mar 24
3
Anne M. Phillips
14 Mar 24
4
JULIAN BAKER
7 Mar 24
3
JULIAN BAKER
7 Mar 24
3
Raymond Cheong
7 Mar 24
SC 13D
Samsara BioCapital, L.P.
5 Mar 24
SC 13D
BAKER BROS. ADVISORS LP
5 Mar 24
3
Initial statement of insider ownership
29 Feb 24
4
SRINIVAS AKKARAJU
29 Feb 24
3
SRINIVAS AKKARAJU
29 Feb 24